Literature DB >> 23008299

Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review.

Electra D Paskett1, Julie A Dean, Jill M Oliveri, J Phil Harrop.   

Abstract

PURPOSE Cancer-related lymphedema (LE) is an incurable condition associated with lymph-involved cancer treatments and is an increasing health, quality of life (QOL), and cost burden on a growing cancer survivor population. This review examines the evidence for causes, risk, prevention, diagnosis, treatment, and impact of this largely unexamined survivorship concern. METHODS PubMed and Medline were searched for cancer-related LE literature published since 1990 in English. The resulting references (N = 726) were evaluated for strength of design, methods, sample size, and recent publication and sorted into categories (ie, causes/prevention, diagnosis, treatment, and QOL). Sixty studies were included. Results Exercise and physical activity and sentinel lymph node biopsy reduce risk, and overweight and obesity increase risk. Evidence that physiotherapy reduces risk and that lymph node status and number of malignant nodes increase risk is less strong. Perometry and bioimpedence emerged as attractive diagnostic technologies, replacing the use of water displacement in clinical practice. Swelling can also be assessed by measuring arm circumference and relying on self-report. Symptoms can be managed, not cured, with complex physical therapy, low-level laser therapy, pharmacotherapy, and surgery. Sequelae of LE negatively affect physical and mental QOL and range in severity. However, the majority of reviewed studies involved patients with breast cancer; therefore, results may not be applicable to all cancers. CONCLUSION Research into causes, prevention, and effect on QOL of LE and information on LE in cancers other than breast is needed. Consensus on definitions and measurement, increased patient and provider awareness of signs and symptoms, and proper and prompt treatment/access, including psychosocial support, are needed to better understand, prevent, and treat LE.

Entities:  

Mesh:

Year:  2012        PMID: 23008299     DOI: 10.1200/JCO.2012.41.8574

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  63 in total

1.  Prospective surveillance of breast cancer-related lymphoedema in the first-year post-surgery: feasibility and comparison of screening measures.

Authors:  J M Blaney; G McCollum; J Lorimer; J Bradley; R Kennedy; J P Rankin
Journal:  Support Care Cancer       Date:  2014-11-16       Impact factor: 3.603

2.  Symptom burden and integrative medicine in cancer survivorship.

Authors:  Susanne M Cutshall; Stephen S Cha; Sheryl M Ness; Daniela L Stan; Sarah A Christensen; Anjali Bhagra; Katharine A Price; Carrie A Thompson; Shahrukh K Hashmi; Tony Y Chon; Tracy J McCray; Amit Sood; Brent A Bauer; Kathryn J Ruddy
Journal:  Support Care Cancer       Date:  2015-02-28       Impact factor: 3.603

3.  Freehand SPECT for image-guided sentinel lymph node biopsy in breast cancer.

Authors:  Christina Bluemel; Andreas Schnelzer; Asli Okur; Alexandra Ehlerding; Stefan Paepke; Klemens Scheidhauer; Marion Kiechle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-11       Impact factor: 9.236

4.  Risk Factors for Arm Lymphedema in a Cohort of Breast Cancer Patients Followed up for 10 Years.

Authors:  René Aloisio da Costa Vieira; Allini Mafra da Costa; Josue Lopes de Souza; Rafael Richieri Coelho; Cleyton Zanardo de Oliveira; Almir José Sarri; Renato José Affonso Junior; Gustavo Zucca-Matthes
Journal:  Breast Care (Basel)       Date:  2015-12-14       Impact factor: 2.860

Review 5.  Manual lymphatic drainage for lymphedema following breast cancer treatment.

Authors:  Jeanette Ezzo; Eric Manheimer; Margaret L McNeely; Doris M Howell; Robert Weiss; Karin I Johansson; Ting Bao; Linda Bily; Catherine M Tuppo; Anne F Williams; Didem Karadibak
Journal:  Cochrane Database Syst Rev       Date:  2015-05-21

6.  Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery.

Authors:  Geraldine Leung; Christina Baggott; Claudia West; Charles Elboim; Steven M Paul; Bruce A Cooper; Gary Abrams; Anand Dhruva; Brian L Schmidt; Kord Kober; John D Merriman; Heather Leutwyler; John Neuhaus; Dale Langford; Betty J Smoot; Bradley E Aouizerat; Christine Miaskowski
Journal:  Lymphat Res Biol       Date:  2014-02-06       Impact factor: 2.589

7.  Survivorship: introduction and definition. Clinical practice guidelines in oncology.

Authors:  Crystal S Denlinger; Robert W Carlson; Madhuri Are; K Scott Baker; Elizabeth Davis; Stephen B Edge; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Elizabeth Kvale; Terry S Langbaum; Jennifer A Ligibel; Mary S McCabe; Kevin T McVary; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Tracey O'Connor; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole McMillian; Deborah Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2014-01       Impact factor: 11.908

8.  Agreement between telerehabilitation involving caregivers and face-to-face clinical assessment of lymphedema in breast cancer survivors.

Authors:  N Galiano-Castillo; A Ariza-García; I Cantarero-Villanueva; C Fernández-Lao; C Sánchez-Salado; M Arroyo-Morales
Journal:  Support Care Cancer       Date:  2013-09-17       Impact factor: 3.603

9.  Treatment-related risk factors for arm lymphedema among long-term breast cancer survivors.

Authors:  Nandita Das; Richard N Baumgartner; Elizabeth C Riley; Christina M Pinkston; Dongyan Yang; Kathy B Baumgartner
Journal:  J Cancer Surviv       Date:  2015-04-26       Impact factor: 4.442

10.  Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study.

Authors:  Marilyn L Kwan; Song Yao; Valerie S Lee; Janise M Roh; Qianqian Zhu; Isaac J Ergas; Qian Liu; Yali Zhang; Susan E Kutner; Charles P Quesenberry; Christine B Ambrosone; Lawrence H Kushi
Journal:  Breast Cancer Res Treat       Date:  2016-07-22       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.